Clinical pharmacologist, neurologist; assistant professor at the Department of Experimental and Clinical Pharmacology at the Medical University of Warsaw. He graduated from the Faculty of Medicine at the Medical University of Warsaw in 1997. He concurrently studied at the Warsaw School of Economics, where he obtained a master’s degree in Economics in 2000. Since 1997, he has been working at the Department of Experimental and Clinical Pharmacology at the Medical University of Warsaw, where he obtained a specialisation in clinical pharmacology. He is a lecturer at the Business School of the Warsaw University of Technology and a specialist at the Therapy and Drug Science Committee of the 5th Faculty of Medical Sciences of the Polish Academy of Sciences. In the years 2000-2006, he was an assistant at the 2nd Neurological Clinic of the Institute of Psychiatry and Neurology. In 2004, he received a PhD in Medical Sciences (his doctoral dissertation concerned the costs of stroke from the social perspective), and in 2013, he was habilitated (based on his work regarding the Hospital Register of Strokes in Poland). Since 2009, he has been the CEO of HealthQuest – a consulting company operating in health technology assessment and reimbursement. He co-authored the health technology assessment guidelines adopted by the Agency for Health Technology Assessment, and also co-authored health technology assessment reports, costs analyses, epidemiological studies and studies concerning quality of life and utility. Maciej Niewada is also one of the founders of the Polish Pharmacoeconomics Society (ISPOR Poland Chapter), where he is currently the President. Furthermore, he cooperates with the Ministry of Health, the National Health Fund and medical scientific societies. His research interests include health technology assessment, pharmacoepidemiology and prevention of cerebrovascular diseases. top
Professor Rafał Niżankowski, MD, PhD is a member of the European Working Group on Medical Angiology IUA. He is initiator of the angiology medical specialisation in Poland, co-founder of the Polish Angiology Society, creator and head of the Angiology Clinic of the Jagiellonian University. He is regional consultant on In the field of angiology and President Elect of the Polish Angiology Society. top
Tanja Novakovic, z wykształcenia magister farmacji, jest dyrektorem spółki ZEM Solutions Ltd oraz przewodniczącą Sekcji Farmakoekonomiki Stowarzyszenia Farmaceutycznego Serbii. Jest absolwentką studiów podyplomowych w zakresie ekonomiki zdrowia na Uniwersytecie w Gandawie w Belgii. Na swoim koncie ma znaczący wkład w rozwój nauki w zakresie ekonomiki zdrowia i HTA oraz organizację licznych międzynarodowych konferencji gromadzących światowych ekspertów z tej dziedziny. Jest autorką pracy „Handbook for pharmacoeconomic evaluations” (2006) – pierwszej publikacji z dziedziny farmakoekonomiki w języku serbskim, serbskich wytycznych farmakoekonomicznych (2011) oraz współautorką książki „Health Economics” (2014). Tanja uczestniczyła w wielu projektach z wielu dziedzin, w tym: Big Data, onkologia, choroby rzadkie, żywienie, reumatologia, leki biopodobne; była również zaangażowana w projekty Banku Światowego oraz serbskiego Ministerstwa Zdrowia. Ponadto organizowała i występowała na wielu krajowych spotkaniach oraz międzynarodowych konferencjach, które zaowocowały międzynarodową współpracą w zakresie edukacji i rozwoju farmakoekonomiki i HTA w Serbii. top
English (UK) 
Polski